DF
MCID: DNG003
MIFTS: 60

Dengue Disease (DF) malady

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Dengue Disease

Aliases & Descriptions for Dengue Disease:

Name: Dengue Disease 38 12 14
Dengue Fever 12 50 3 14 69
Dengue 52 41 42
Dengue Shock Syndrome 50 69
Df 50 3
Philippine Hemorrhagic Fever 50
Singapore Hemorrhagic Fever 50
Dengue Hemorrhagic Fever 50
Dengue Virus Infection 50
Thai Hemorrhagic Fever 50
Hemorrhagic Dengue 50
Classical Dengue 12
Breakbone Fever 12
Classic Dengue 12
Severe Dengue 69

Classifications:



External Ids:

Disease Ontology 12 DOID:12205
ICD10 33 A90
ICD9CM 35 061
MeSH 42 D003715
NCIt 47 C34528
UMLS 69 C0011311

Summaries for Dengue Disease

MedlinePlus : 41 dengue is an infection caused by a virus. you can get it if an infected mosquito bites you. dengue does not spread from person to person. it is common in warm, wet areas of the world. outbreaks occur in the rainy season. dengue is rare in the united states. symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. in some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from your nose, gums, or under your skin. it can also become dengue shock syndrome, which causes massive bleeding and shock. these forms of dengue are life-threatening. there is no specific treatment. most people with dengue recover within 2 weeks. until then, drinking lots of fluids, resting and taking non-aspirin fever-reducing medicines might help. people with the more severe forms of dengue usually need to go to the hospital and get fluids. to lower your risk when traveling to areas where dengue is found wear insect repellent with deet wear clothes that cover your arms, legs and feet close unscreened doors and windows nih: national institute of allergy and infectious diseases

MalaCards based summary : Dengue Disease, also known as dengue fever, is related to dengue fever, protection against and dengue hemorrhagic fever, and has symptoms including fever, severe headache and severe pain behind the eyes. An important gene associated with Dengue Disease is CD209 (CD209 Molecule), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and eye, and related phenotypes are hematopoietic system and immune system

CDC : 3 With more than one-third of the world’s population living in areas at risk for infection, dengue virus is a leading cause of illness and death in the tropics and subtropics. As many as 400 million people are infected yearly. Dengue is caused by any one of four related viruses transmitted by mosquitoes. There are not yet any vaccines to prevent infection with dengue virus and the most effective protective measures are those that avoid mosquito bites. When infected, early recognition and prompt supportive treatment can substantially lower the risk of medical complications and death.

Disease Ontology : 12 A viral infectious disease that results_in infection, has material basis in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted_by Aedes mosquito bite. The infection has symptom fever, has symptom severe headache, has symptom severe pain behind the eyes, has symptom joint pain, has symptom muscle and bone pain, has symptom rash, and has symptom mild bleeding.

Related Diseases for Dengue Disease

Diseases related to Dengue Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 45)
id Related Disease Score Top Affiliating Genes
1 dengue fever, protection against 12.3
2 dengue hemorrhagic fever 10.8
3 dengue shock syndrome 10.8
4 asymptomatic dengue 10.8
5 indomethacin antenatal infection 10.3 CD40LG MBL2
6 tonsil cancer 10.3 CD40LG ICAM1
7 trichostrongyloidiasis 10.2 CD40LG PIK3C2A
8 dislocation of ear ossicle 10.2 CD40LG ICAM1 VCAM1
9 erysipelas 10.2 CD40LG RAF1
10 acute kidney tubular necrosis 10.2 CD40LG PIK3C2A
11 erb-duchenne and dejerine-klumpke palsies 10.2 CCL5 ICAM1 VCAM1
12 pemphigus vulgaris, familial 10.2 CD40LG ICAM1 VCAM1
13 orofacial granulomatosis 10.2 CCL5 ICAM1 VCAM1
14 mineral metabolism disease 10.2 CCL5 CD209 CD40LG
15 hyperimmunoglobulin syndrome 10.2 CCL5 CD209 CD40LG
16 hemorrhagic fever with renal syndrome 10.2 CD40LG PIK3C2A
17 pigmentation disease 10.2 CCL5 ICAM1 VCAM1
18 cytokine receptor deficiency 10.2 IL11 THPO
19 bare lymphocyte syndrome, type i 10.2 CCL5 ICAM1 VCAM1
20 immunoglobulin g deficiency 10.2 CCL5 CD40LG THPO
21 polg-related disorders 10.2 PTPN11 RAF1
22 israeli tick typhus 10.2 CCL5 CD40LG
23 anus leiomyosarcoma 10.2 CCL5 CD209 CD40LG
24 brown's tendon sheath syndrome 10.2 ICAM1 PIK3C2A VCAM1
25 pseudomonas stutzeri infections 10.1 PTPN11 RAF1
26 eating disorder 10.1 CD40LG ICAM1 VCAM1
27 hypopyon ulcer 10.1 ICAM1 VCAM1
28 acute chest syndrome 10.1 CCL5 CD40LG ICAM1
29 craniopharyngioma 10.1 FCGR1A ICAM1 VCAM1
30 microscopic breast papilloma 10.1 CD40LG ICAM1 PIK3C2A
31 complex regional pain syndrome 10.1 CCL5 CD40LG ICAM1
32 plantar fasciitis 10.1 CCL5 CD209 CD40LG VCAM1
33 malignant peritoneal solitary fibrous tumor 10.1 CCL5 ICAM1 VCAM1
34 rdh12-related leber congenital amaurosis 10.1 PTPN11 RAF1
35 advanced sleep phase syndrome, familial, 1 10.1 CCL5 CD40LG ICAM1 VCAM1
36 macrodactyly of the foot 10.1 ICAM1 VCAM1
37 heart valve disease 10.1 CD40LG ICAM1 VCAM1
38 rectum squamous cell carcinoma 10.0 CCL5 CD40LG MBL2 PIK3C2A
39 rheumatoid arthritis 10.0 CCL5 CD40LG ICAM1 IL11 VCAM1
40 nemaline myopathy 2, autosomal recessive 9.8 CCL5 CD40LG ICAM1 IL11 VCAM1
41 cousin syndrome 9.8 CCL5 CD40LG FCGR1A ICAM1 MBL2 VCAM1
42 endotheliitis 9.6
43 thrombocytopenia 9.5
44 hemorrhagic fever 9.5
45 dentinogenesis imperfecta 8.1 CCL5 CD209 CD40LG FCGR1A HCFC1 ICAM1

Graphical network of the top 20 diseases related to Dengue Disease:



Diseases related to Dengue Disease

Symptoms & Phenotypes for Dengue Disease

Symptoms:

12
  • fever
  • severe headache
  • severe pain behind the eyes
  • joint pain
  • muscle
  • rash
  • mild bleeding

Human phenotypes related to Dengue Disease:

32 (show all 22)
id Description HPO Frequency HPO Source Accession
1 pruritus 32 HP:0000989
2 arthralgia 32 HP:0002829
3 fever 32 HP:0001945
4 headache 32 HP:0002315
5 abdominal pain 32 HP:0002027
6 diarrhea 32 HP:0002014
7 nausea and vomiting 32 HP:0002017
8 lethargy 32 HP:0001254
9 hypotension 32 HP:0002615
10 hepatomegaly 32 HP:0002240
11 ascites 32 HP:0001541
12 thrombocytopenia 32 HP:0001873
13 gastrointestinal hemorrhage 32 HP:0002239
14 epistaxis 32 HP:0000421
15 skin rash 32 HP:0000988
16 bruising susceptibility 32 HP:0000978
17 gingival bleeding 32 HP:0000225
18 petechiae 32 HP:0000967
19 cerebral hemorrhage 32 HP:0001342
20 leukopenia 32 HP:0001882
21 hypoproteinemia 32 HP:0003075
22 cardiorespiratory arrest 32 HP:0006543

UMLS symptoms related to Dengue Disease:


fever, pruritus

MGI Mouse Phenotypes related to Dengue Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.65 CCL5 CD40LG FCGR1A ICAM1 MBL2 PIK3C2A
2 immune system MP:0005387 9.32 CCL5 CD40LG FCGR1A ICAM1 MBL2 PIK3C2A

Drugs & Therapeutics for Dengue Disease

Drugs for Dengue Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
2
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
3 Vaccines Phase 4,Phase 3,Phase 1,Phase 2
4 Anti-Allergic Agents Phase 4
5 Antipruritics Phase 4
6 Dermatologic Agents Phase 4
7 Histamine Antagonists Phase 4
8 Histamine H1 Antagonists Phase 4
9
Histamine Phosphate Phase 4 51-74-1 65513
10 Neurotransmitter Agents Phase 4
11
Ivermectin Approved, Vet_approved Phase 2, Phase 3 70288-86-7 6474909 46936176
12 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
13 DEET Phase 3
14 Insect Repellents Phase 3
15 Protective Agents Phase 3
16 Anti-Infective Agents Phase 2, Phase 3,Phase 1
17 Antiparasitic Agents Phase 2, Phase 3,Phase 1
18 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
19
chloroquine Approved, Vet_approved Phase 1, Phase 2 54-05-7 2719
20
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754 657311
21
Ribavirin Approved Phase 2 36791-04-5 37542
22
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
23 Analgesics Phase 1, Phase 2
24 Analgesics, Non-Narcotic Phase 1, Phase 2
25 Anthelmintics Phase 1, Phase 2
26 Anti-Inflammatory Agents Phase 1, Phase 2
27 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
28 Antimalarials Phase 1, Phase 2
29 Antiprotozoal Agents Phase 1, Phase 2
30 Antirheumatic Agents Phase 1, Phase 2
31 Chloroquine diphosphate Phase 1, Phase 2 50-63-5
32 Peripheral Nervous System Agents Phase 1, Phase 2
33 Antimetabolites Phase 2
34 Antiviral Agents Phase 2
35 Cortisol succinate Phase 2
36 Hydrocortisone 17-butyrate 21-propionate Phase 2
37 Hydrocortisone acetate Phase 2
38 Antibodies Phase 1, Phase 2
39 Immunoglobulins Phase 1, Phase 2
40 Coagulants Phase 2
41 Hemostatics Phase 2
42
Aluminum hydroxide Approved Phase 1 21645-51-2
43 Adjuvants, Immunologic Phase 1
44 Aluminum sulfate Phase 1
45 Antacids Phase 1
46 Anti-Ulcer Agents Phase 1
47 Gastrointestinal Agents Phase 1
48 Papaya Nutraceutical Phase 1
49
Acetaminophen Approved 103-90-2 1983
50
Artesunate Approved 88495-63-0 6917864 5464098

Interventional clinical trials:

(show top 50) (show all 157)
id Name Status NCT ID Phase
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Recruiting NCT02673840 Phase 4
2 Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study) Recruiting NCT02555072 Phase 4
3 Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS) Unknown status NCT00966628 Phase 3
4 Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR Unknown status NCT00938379 Phase 3
5 Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
6 Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
7 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Completed NCT01411241 Phase 3
8 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
9 Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine Recruiting NCT02406729 Phase 3
10 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® Recruiting NCT02979535 Phase 3
11 Efficacy and Safety of Ivermectin Against Dengue Infection Recruiting NCT02045069 Phase 2, Phase 3
12 Study of INTERCEPT Blood System for Red Blood Cells in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS) Recruiting NCT03037164 Phase 3
13 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Active, not recruiting NCT01373281 Phase 3
14 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Active, not recruiting NCT01374516 Phase 3
15 Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Active, not recruiting NCT02747927 Phase 3
16 Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Not yet recruiting NCT02992418 Phase 3
17 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® Not yet recruiting NCT02993757 Phase 3
18 The Effect of Chloroquine in the Treatment of Patients With Dengue Unknown status NCT00849602 Phase 1, Phase 2
19 Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms Unknown status NCT01973855 Phase 2
20 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children Completed NCT00384670 Phase 1, Phase 2
21 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants Completed NCT00322049 Phase 1, Phase 2
22 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Completed NCT01550289 Phase 2
23 A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
24 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore Completed NCT00880893 Phase 2
25 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Completed NCT01187433 Phase 2
26 A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults Completed NCT00239577 Phase 2
27 A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children Completed NCT01843621 Phase 1, Phase 2
28 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Completed NCT01488890 Phase 2
29 Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
30 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Completed NCT00875524 Phase 2
31 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
32 Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Completed NCT00730288 Phase 2
33 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Completed NCT00993447 Phase 2
34 Efficacy and Safety of Dengue Vaccine in Healthy Children Completed NCT00842530 Phase 2
35 Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia Completed NCT01218906 Phase 2
36 Study of Febrile Illness for Dengue-Endemic Areas in Latin America Completed NCT01293331 Phase 1, Phase 2
37 A Phase II Trial of a WRAIR Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults Completed NCT00350337 Phase 2
38 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed NCT00788151 Phase 2
39 Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) Completed NCT02193087 Phase 2
40 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years Completed NCT01511250 Phase 2
41 Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Completed NCT00740155 Phase 2
42 A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand Completed NCT00370682 Phase 2
43 Celgosivir as a Treatment Against Dengue Completed NCT01619969 Phase 1, Phase 2
44 A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children Completed NCT00468858 Phase 2
45 Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever Completed NCT01601613 Phase 2
46 The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans Completed NCT01943305 Phase 2
47 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule Recruiting NCT02824198 Phase 2
48 Safety and Immunogenicity of Takeda's TDV in Healthy Children Recruiting NCT02948829 Phase 2
49 Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand Recruiting NCT02332733 Phase 2
50 Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults Recruiting NCT02421367 Phase 1, Phase 2

Search NIH Clinical Center for Dengue Disease

Cochrane evidence based reviews: dengue

Genetic Tests for Dengue Disease

Anatomical Context for Dengue Disease

MalaCards organs/tissues related to Dengue Disease:

39
Skin, Bone, Eye, Thyroid, Endothelial, Liver, Nk Cells

Publications for Dengue Disease

Articles related to Dengue Disease:

(show top 50) (show all 86)
id Title Authors Year
1
Dengue Disease Modelling and Forecasting: Utility and Limitations. ( 27292001 )
2016
2
Symptomatic Dengue Disease in Five Southeast Asian Countries: Epidemiological Evidence from a Dengue Vaccine Trial. ( 27532617 )
2016
3
Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease. ( 27506852 )
2016
4
Clinical and laboratory signs associated to severe dengue disease in hospitalized children. ( 27112034 )
2016
5
Relative Contribution of Dengue IgG Antibodies Acquired during Gestation or Breastfeeding in Mediating Dengue Disease Enhancement and Protection in Type I Interferon Receptor-Deficient Mice. ( 27341339 )
2016
6
Seasonal Distribution and Climatic Correlates of Dengue Disease in Dhaka, Bangladesh. ( 27114293 )
2016
7
High prevalence of clinically unsuspected dengue disease among children in Ribeirao Preto City, Brazil. ( 27004990 )
2016
8
Early diagnosis of dengue disease severity in a resource-limited Asian country. ( 27670906 )
2016
9
Mannose-binding lectin gene (MBL2) polymorphisms related to the mannose-binding lectin low levels are associated to dengue disease severity. ( 27180198 )
2016
10
Dengue Disease Risk Mental Models in the City of Dhaka, Bangladesh: Juxtapositions and Gaps Between the Public and Experts. ( 26387980 )
2015
11
Antibody-enhanced dengue disease generates a marked CNS inflammatory response in the black-tufted marmoset Callithrix penicillata. ( 26303046 )
2015
12
Biomarkers of severe dengue disease - a review. ( 26462910 )
2015
13
Epidemiological trends of dengue disease in Colombia (2000-2011): a systematic review. ( 25790245 )
2015
14
Dengue disease outbreak definitions are implicitly variable. ( 25979287 )
2015
15
Epidemiological and demographic characteristics of dengue disease at a tertiary care centre in Saurashtra region during the year 2013. ( 26714509 )
2015
16
Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models. ( 26001278 )
2015
17
Antibodies against immature virions are not a discriminating factor for dengue disease severity. ( 25760350 )
2015
18
Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. ( 26220099 )
2015
19
Evolution of dengue disease and entomological monitoring in Santa Cruz, Bolivia 2002 - 2008. ( 25706631 )
2015
20
Dengue disease surveillance: an updated systematic literature review. ( 24889501 )
2014
21
Association between proinflammatory cytokines and lipid peroxidation in patients with severe dengue disease around defervescence. ( 24216294 )
2014
22
Epidemiological trends of dengue disease in Mexico (2000-2011): a systematic literature search and analysis. ( 25375162 )
2014
23
Dengue disease outbreak detection. ( 25160360 )
2014
24
Epidemiology of dengue disease in malaysia (2000-2012): a systematic literature review. ( 25375211 )
2014
25
CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice. ( 25217165 )
2014
26
Evaluation of the WHO classification of dengue disease severity during an epidemic in 2011 in the state of CearA!, Brazil. ( 24626308 )
2014
27
Reviewing the literature for epidemiological trends of dengue disease: introduction to a series of seven national systematic literature reviews. ( 25375830 )
2014
28
Dengue disease surveillance: improving data for dengue control. ( 25375232 )
2014
29
NK Cells during Dengue Disease and Their Recognition of Dengue Virus-Infected cells. ( 24829565 )
2014
30
Predictive symptoms and signs of severe dengue disease for patients with dengue fever: a meta-analysis. ( 25097856 )
2014
31
First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies. ( 24699622 )
2014
32
Epidemiology of Dengue Disease in the Philippines (2000-2011): A Systematic Literature Review. ( 25375119 )
2014
33
Epidemiological trends of dengue disease in Thailand (2000-2011): a systematic literature review. ( 25375766 )
2014
34
Atypical presentations of dengue disease in the elderly visiting the ED. ( 23399333 )
2013
35
Epidemiological trends of dengue disease in Brazil (2000-2010): a systematic literature search and analysis. ( 24386496 )
2013
36
Spatial distribution of dengue disease in municipality of MossorA^, Rio Grande do Norte, using the Geographic Information System. ( 24896274 )
2013
37
Comment on: "Atypical presentations of dengue disease in the elderly visiting the ED" ( 24342867 )
2013
38
Assessing weather effects on dengue disease in malaysia. ( 24287855 )
2013
39
Can non-human primates serve as models for investigating dengue disease pathogenesis? ( 24130557 )
2013
40
Knowledge, attitude, and practice of dengue disease among healthcare professionals in southern Taiwan. ( 23332425 )
2013
41
The battle between infection and host immune responses of dengue virus and its implication in dengue disease pathogenesis. ( 23476150 )
2013
42
Dogma in classifying dengue disease. ( 23926138 )
2013
43
An optimal control problem arising from a dengue disease transmission model. ( 23274179 )
2013
44
Association of human immune response to Aedes aegypti salivary proteins with dengue disease severity. ( 21995849 )
2012
45
Simple Prognostic Criteria can Definitively Identify Patients who Develop Severe Versus Non-Severe Dengue Disease, or Have Other Febrile Illnesses. ( 22383925 )
2012
46
Environmental influences on antibody-enhanced dengue disease outcomes. ( 23295753 )
2012
47
Characterization of early host responses in adults with dengue disease. ( 21810247 )
2011
48
Clinical and virological factors influencing the performance of a NS1 antigen-capture assay and potential use as a marker of dengue disease severity. ( 21811645 )
2011
49
Dengue disease status in Chennai (2006-2008): a retrospective analysis. ( 21441688 )
2011
50
Unfolded protein response (UPR) gene expression during antibody-dependent enhanced infection of cultured monocytes correlates with dengue disease severity. ( 20858223 )
2011

Variations for Dengue Disease

Expression for Dengue Disease

LifeMap Discovery
Genes differentially expressed in tissues of Dengue Disease patients vs. healthy controls: 35 (show top 50) (show all 93)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFI27 interferon, alpha-inducible protein 27 Blood + 4.85 0.000
2 RRM2 ribonucleotide reductase M2 Blood + 4.48 0.000
3 CEP55 centrosomal protein 55kDa Blood + 4.33 0.000
4 BIRC5 baculoviral IAP repeat containing 5 Blood + 4.30 0.000
5 XIST X inactive specific transcript (non-protein coding) Blood - 4.25 0.009
6 CD38 CD38 molecule Blood + 4.23 0.000
7 DLGAP5 discs, large (Drosophila) homolog-associated protein 5 Blood + 4.10 0.000
8 BUB1 BUB1 mitotic checkpoint serine/threonine kinase Blood + 4.08 0.000
9 IGHM immunoglobulin heavy constant mu Blood + 4.04 0.000
10 MCM10 minichromosome maintenance 10 replication initiation factor Blood + 3.99 0.000
11 SHCBP1 SHC SH2-domain binding protein 1 Blood + 3.97 0.000
12 PBK PDZ binding kinase Blood + 3.97 0.000
13 TYMS thymidylate synthetase Blood + 3.96 0.000
14 PI3 peptidase inhibitor 3, skin-derived Blood - 3.93 0.000
15 CDCA2 cell division cycle associated 2 Blood + 3.91 0.000
16 SESN3 sestrin 3 Blood - 3.90 0.000
17 HMMR hyaluronan-mediated motility receptor (RHAMM) Blood + 3.83 0.000
18 MKI67 marker of proliferation Ki-67 Blood + 3.83 0.000
19 ZWINT ZW10 interacting kinetochore protein Blood + 3.83 0.000
20 DTL denticleless E3 ubiquitin protein ligase homolog (Drosophila) Blood + 3.80 0.000
21 CDK1 cyclin-dependent kinase 1 Blood + 3.78 0.000
22 NCAPG non-SMC condensin I complex, subunit G Blood + 3.76 0.000
23 CDT1 chromatin licensing and DNA replication factor 1 Blood + 3.76 0.000
24 SPC25 SPC25, NDC80 kinetochore complex component Blood + 3.75 0.000
25 CDC20 cell division cycle 20 Blood + 3.73 0.000
26 CNTNAP3 contactin associated protein-like 3 Blood - 3.72 0.000
27 TOP2A topoisomerase (DNA) II alpha Blood + 3.71 0.000
28 NOV nephroblastoma overexpressed Blood - 3.71 0.000
29 EIF1AY eukaryotic translation initiation factor 1A, Y-linked Blood + 3.69 0.015
30 CCNB2 cyclin B2 Blood + 3.62 0.000
31 CDKN3 cyclin-dependent kinase inhibitor 3 Blood + 3.62 0.000
32 KIAA0101 KIAA0101 Blood + 3.61 0.000
33 KIF2C kinesin family member 2C Blood + 3.60 0.000
34 TK1 thymidine kinase 1, soluble Blood + 3.59 0.000
35 RPS4Y1 ribosomal protein S4, Y-linked 1 Blood + 3.57 0.017
36 TTK TTK protein kinase Blood + 3.56 0.000
37 CDC6 cell division cycle 6 Blood + 3.56 0.000
38 CAV1 caveolin 1, caveolae protein, 22kDa Blood + 3.56 0.000
39 CENPA centromere protein A Blood + 3.54 0.000
40 CYAT1 immunoglobulin lambda light chain-like Blood + 3.52 0.000
41 ASPM abnormal spindle microtubule assembly Blood + 3.52 0.000
42 OR2W3 olfactory receptor, family 2, subfamily W, member 3 Blood - 3.51 0.000
43 UHRF1 ubiquitin-like with PHD and ring finger domains 1 Blood + 3.50 0.000
44 SELENBP1 selenium binding protein 1 Blood - 3.50 0.000
45 GINS2 GINS complex subunit 2 (Psf2 homolog) Blood + 3.49 0.000
46 MELK maternal embryonic leucine zipper kinase Blood + 3.47 0.000
47 BUB1B BUB1 mitotic checkpoint serine/threonine kinase B Blood + 3.47 0.000
48 CHEK1 checkpoint kinase 1 Blood + 3.46 0.000
49 CCNB1 cyclin B1 Blood + 3.45 0.000
50 KIF11 kinesin family member 11 Blood + 3.42 0.000
Search GEO for disease gene expression data for Dengue Disease.

Pathways for Dengue Disease

Pathways related to Dengue Disease according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 CCL5 CD209 CD40LG FCGR1A ICAM1 IL11
2
Show member pathways
13.25 CD209 CD40LG FCGR1A ICAM1 PTPN11 RAF1
3
Show member pathways
12.97 CCL5 CD40LG FCGR1A ICAM1 IL11 PTPN11
4
Show member pathways
12.35 FCGR1A ICAM1 PTPN11 VCAM1
5
Show member pathways
12.19 ICAM1 PTPN11 RAF1 VCAM1
6
Show member pathways
11.94 IL11 PTPN11 RAF1 THPO
7 11.9 IL11 THPO VCAM1
8
Show member pathways
11.86 CCL5 CD209 HCFC1 ICAM1 IVNS1ABP PTPN11
9 11.84 CD209 IL11 THPO
10 11.78 CCL5 ICAM1 VCAM1
11 11.75 CD40LG FCGR1A ICAM1 VCAM1
12 11.71 FCGR1A IL11 THPO
13 11.69 CD40LG ICAM1 VCAM1
14 11.64 CCL5 ICAM1 IL11
15 11.5 CD40LG ICAM1 VCAM1
16
Show member pathways
11.43 CD40LG ICAM1 VCAM1
17 11.36 FCGR1A ICAM1 MBL2
18 11.23 CD40LG ICAM1 VCAM1
19 11.1 ICAM1 PTPN11 RAF1 VCAM1
20 10.95 CD209 RAF1
21 10.9 ICAM1 IL11 PTPN11 RAF1
22 10.78 ICAM1 VCAM1

GO Terms for Dengue Disease

Cellular components related to Dengue Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 CCL5 CD40LG ICAM1 IL11 MBL2 THPO
2 external side of plasma membrane GO:0009897 9.26 CD209 CD40LG ICAM1 VCAM1
3 cell surface GO:0009986 9.02 CD209 CD40LG ICAM1 MBL2 VCAM1

Biological processes related to Dengue Disease according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.72 CD209 HCFC1 ICAM1 IVNS1ABP VCAM1
2 platelet activation GO:0030168 9.71 CD40LG PTPN11 RAF1
3 cellular response to tumor necrosis factor GO:0071356 9.7 CCL5 ICAM1 VCAM1
4 regulation of immune response GO:0050776 9.67 CD40LG FCGR1A ICAM1 VCAM1
5 interferon-gamma-mediated signaling pathway GO:0060333 9.63 FCGR1A ICAM1 VCAM1
6 B cell differentiation GO:0030183 9.61 CD40LG IL11 VCAM1
7 positive regulation of T cell proliferation GO:0042102 9.58 CCL5 CD40LG VCAM1
8 regulation of protein complex assembly GO:0043254 9.51 HCFC1 PTPN11
9 neurotrophin TRK receptor signaling pathway GO:0048011 9.49 PTPN11 RAF1
10 negative regulation of hormone secretion GO:0046888 9.48 IL11 PTPN11
11 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.35 CCL5 ICAM1 PTPN11 RAF1 THPO
12 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.33 CD209 ICAM1 VCAM1
13 membrane to membrane docking GO:0022614 9.26 ICAM1 VCAM1
14 leukocyte cell-cell adhesion GO:0007159 9.02 CCL5 CD209 CD40LG ICAM1 VCAM1

Molecular functions related to Dengue Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mannose binding GO:0005537 8.96 CD209 MBL2
2 cytokine activity GO:0005125 8.92 CCL5 CD40LG IL11 THPO

Sources for Dengue Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....